Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.

Cancer Discov
Authors
Keywords
Abstract

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods.

Year of Publication
2013
Journal
Cancer Discov
Volume
3
Issue
10
Pages
1108-12
Date Published
2013 Oct
ISSN
2159-8290
URL
DOI
10.1158/2159-8290.CD-13-0219
PubMed ID
24124232
PubMed Central ID
PMC3800055
Links
Grant list
U24 CA160034 / CA / NCI NIH HHS / United States
U24 CA159988 / CA / NCI NIH HHS / United States
U24CA159988 / CA / NCI NIH HHS / United States
U24CA160036 / CA / NCI NIH HHS / United States
U24 CA160036 / CA / NCI NIH HHS / United States
U24 CA160019 / CA / NCI NIH HHS / United States
U24 CA160035 / CA / NCI NIH HHS / United States
U24CA160034 / CA / NCI NIH HHS / United States
U24CA160035 / CA / NCI NIH HHS / United States
U24CA160019 / CA / NCI NIH HHS / United States